Delayed Effects of Treatment in Cancer Survivors (DETECS)

Specific Aim 1: To compare markers of ovarian reserve between cancer survivors and healthy controls. Hypothesis: Cancer survivors will have lower serum Anti-Mullerian Hormone (AMH) and antral follicle count (AFC), and higher Follicle Stimulating Hormone (FSH) than healthy controls. Specific Aim 2: To compare cardio-metabolic, endocrine and bone profiles between cancer survivors and controls using a combination of anthropometric measures, fasting serum markers, and urinary markers of bone health. Hypothesis: Cancer survivors will have higher total cholesterol and lower 25-OH vitamin D than healthy controls. Specific Aim 3: To evaluate potential associations between ovarian reserve and markers of metabolism, obesity, and tumor bone health in young female cancer survivors. Hypothesis: As BMI and total cholesterol increases, serum AMH will decrease. Specific Aim 4: To compare quality of life markers, as assessed by validated instruments, between cancer survivors and controls using recommended scoring techniques. Hypothesis: Cancer survivors will have lower quality of life markers as compared to controls. The investigators will conduct a prospective study to characterize the quality of life and cardio-metabolic, endocrine, and bone profiles of female cancer survivors using a combination of anthropometric, serum, urinary, and ultrasonographic markers in combination with QOL instruments.